{"schema":"hottub-news/story/v1","story":"st_3ttetgcegmixd4ejy46a","title":"Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer","title_en":null,"outlets":3,"brief":null,"page":"https://hottub.news/stories/akeso-announces-first-patient-enrolled-in-global-phase-iii-trial-of-3ttetgcegm","count":3,"items":[{"id":"n_if4jlfzpbpgzpbd46cpa","seq":336558,"kind":"article","title":"Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer","url":"https://www.prnewswire.com/news-releases/akeso-announces-first-patient-enrolled-in-global-phase-iii-trial-of-cadonilimab-versus-nivolumab-in-first-line-gastric-cancer-302891043.html","published":"2026-09-28T04:08:17Z","seen":"2026-09-28T04:08:17Z","lang":"en","source":{"id":"prnewswire.com","name":"prnewswire.com","domain":"prnewswire.com","outlet":{"wikidata":"Q376399","name":"PR Newswire","type":"other","country":"US","designations":["business","information resource"]}},"via":"gdelt-gkg-english","topics":["economy","education","science","business"],"authors":["Akeso","Inc."],"entities":[{"id":"Q132735866","name":"Akeso","type":"org"},{"id":"Q123585479","name":"cadonilimab","type":"other"},{"id":"Q7041828","name":"nivolumab","type":"other"}],"story":"st_3ttetgcegmixd4ejy46a","category":"health","category_p":0.6700000166893005,"sentiment":"positive","tone":0.07999999821186066,"political":0.05999999865889549},{"id":"n_oyxls3ouq2ymi3ohla4q","seq":353119,"kind":"article","title":"Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer","url":"https://www.manilatimes.net/2026/09/28/tmt-newswire/pr-newswire/akeso-announces-first-patient-enrolled-in-global-phase-iii-trial-of-cadonilimab-versus-nivolumab-in-first-line-gastric-cancer/2433771","published":"2026-09-28T03:56:00Z","seen":"2026-09-28T06:06:31Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["economy","health","politics","business"],"entities":[{"id":"Q376399","name":"PR Newswire","type":"org"}],"story":"st_3ttetgcegmixd4ejy46a","category":"health","category_p":0.6700000166893005,"sentiment":"positive","tone":0.09000000357627869,"political":0.05999999865889549},{"id":"n_3ttetgcegmixd4ejy46a","seq":335247,"kind":"article","title":"Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer","url":"https://www.thailand-business-news.com/pr-news/akeso-announces-first-patient-enrolled-in-global-phase-iii-trial-of-cadonilimab-versus-nivolumab-in-first-line-gastric-cancer","published":"2026-09-28T03:43:19Z","seen":"2026-09-28T03:43:19Z","lang":"en","source":{"id":"thailand-business-news.com","name":"thailand-business-news.com","domain":"thailand-business-news.com","outlet":{"wikidata":"Q120063840","name":"Thailand Business News","type":"newspaper","country":"TH","designations":["newspaper"]}},"via":"gdelt-gkg-english","topics":["education","economy","politics","science"],"entities":[{"id":"Q132735866","name":"Akeso","type":"org"},{"id":"Q123585479","name":"cadonilimab","type":"other"},{"id":"Q7041828","name":"nivolumab","type":"other"},{"id":"Q189588","name":"stomach cancer","type":"other"}],"story":"st_3ttetgcegmixd4ejy46a","category":"health","category_p":0.6700000166893005,"sentiment":"positive","tone":0.07000000029802322,"political":0.05999999865889549}]}